Company intelligence / Profile preview

Senexis

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Development stage: Other

Overview

Senexis was a UK-based biopharmaceutical company focused on the discovery and development of small molecule drugs to treat aging-related diseases caused by amyloidosis. The company's primary research centered on inhibiting the aggregation and toxicity of amyloid-beta (Aβ) peptides, which are implicated in the pathogenesis of Alzheimer's disease. Senexis also explored treatments for Type 2 diabetes by targeting islet amyloid polypeptide (IAPP). In 2010, the company was acquired by BTG plc, which sought to integrate Senexis's Alzheimer's programs into its specialty pharmaceuticals portfolio.

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Wellcome Trust

Beyond the preview

Go deeper on Senexis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Senexis.

Explore the full profile